UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential
June 07, 2013 at 12:30 PM EDT
In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV ), but lowered the price target from $54.00 to $51.00. In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and
